Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Diphenhydramine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH1 known ✓ | P35367 | 4/20 | 0.81 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 1.00 |
| ▸ | LMNA | P02545 | 6/20 | 0.81 |
| ▸ | CHRM2 | P08172 | 5/20 | 0.81 |
| ▸ | SLC6A2 | P23975 | 5/20 | 0.81 |
| ▸ | SLC6A3 | Q01959 | 5/20 | 0.81 |
| ▸ | CYP2D6 | P10635 | 5/20 | 0.81 |
| ▸ | ADRA2A | P08913 | 4/20 | 0.81 |
| ▸ | CHRM1 | P11229 | 4/20 | 0.81 |
| ▸ | ADRA2B | P18089 | 4/20 | 0.81 |
| ▸ | CHRM4 | P08173 | 3/20 | 0.81 |
| ▸ | CHRM5 | P08912 | 3/20 | 0.81 |
| ▸ | CHRM3 | P20309 | 3/20 | 0.81 |
| ▸ | HTR2A | P28223 | 3/20 | 0.81 |
| ▸ | HTR2C | P28335 | 3/20 | 0.81 |
| ▸ | HTR2B | P41595 | 3/20 | 0.81 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.81 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.81 |
| ▸ | ADRA1D | P25100 | 1/20 | 0.81 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.81 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Diphenhydramine SCHEMBL1896940 | 0.90 | LMNA (1.00) | SMN1; SMN2LMNACHRM2SLC6A2SLC6A3 | |
| Diphenhydramine SCHEMBL5128 | 0.90 | LMNA (1.00) | SMN1; SMN2LMNACHRM2SLC6A2SLC6A3 | |
| Diphenhydramine SCHEMBL5670807 | 0.90 | LMNA (1.00) | SMN1; SMN2LMNACHRM2SLC6A2SLC6A3 | |
| Diphenhydramine SCHEMBL5085363 | 0.89 | ALDH1A1 (0.91) | SMN1; SMN2LMNACHRM2SLC6A2SLC6A3 | |
| Diphenhydramine SCHEMBL10385770 | 0.89 | LMNA (0.98) | SMN1; SMN2LMNACHRM2SLC6A2SLC6A3 | |
| Diphenhydramine SCHEMBL7933565 | 0.89 | LMNA (0.98) | SMN1; SMN2LMNACHRM2SLC6A2SLC6A3 | |
| Diphenhydramine SCHEMBL19259450 | 0.88 | LMNA (0.88) | SMN1; SMN2LMNACHRM2SLC6A2SLC6A3 | |
| Diphenhydramine SCHEMBL8575800 | 0.88 | ALDH1A1 (0.88) | SMN1; SMN2LMNACHRM2SLC6A2SLC6A3 | |
| Diphenhydramine SCHEMBL28213087 | 0.87 | LMNA (0.94) | SMN1; SMN2LMNACHRM2SLC6A2SLC6A3 | |
| Diphenhydramine SCHEMBL8846483 | 0.86 | LMNA (0.89) | SMN1; SMN2LMNACHRM2SLC6A2SLC6A3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8703823-B2 | Methods for treatment of migraine and symptoms thereof | SALEHANI FOAD (US) | 2014-04-22 | — | — | US | disclosed |
| US-20090018205-A1 | METHODS FOR TREATMENT OF MIGRAINE AND SYMPTOMS THEREOF | SALEHANI FOAD | 2009-01-15 | — | — | US | disclosed |
| US-20050282879-A1 | Methods and composition for treatment of migraine and symptoms thereof | SALEHANI FOAD | 2005-12-22 | — | — | US | disclosed |
| EP-0817618-A1 | SOFT GELATIN CAPSULE WITH A GELATIN SHELL COMPRISING XANTHINE DERIVATIVE | THE PROCTER & GAMBLE COMPANY (US) | 1998-01-14 | — | — | EP | disclosed |
| US-5641512-A | SHELL CONTAINS XANTHINE DERIVATIVE | THE PROCTER & GAMBLE COMPANY (US) | 1997-06-24 | — | — | US | disclosed |
| EP-0741560-A1 | PROCESS FOR SOLUBILIZING DIFFICULTLY SOLUBLE PHARMACEUTICAL ACTIVES | THE PROCTER & GAMBLE COMPANY (US) | 1996-11-13 | — | — | EP | disclosed |
| WO-1996029997-A1 | SOFT GELATIN CAPSULE WITH A GELATIN SHELL COMPRISING XANTHINE DERIVATIVE | THE PROCTER & GAMBLE COMPANY (US) | 1996-10-03 | — | — | WO | disclosed |
| US-5510389-A | CONTAINING ACETAMINOPHEN FORMED BY ADDING AN ELECTROPHILIC BECKMAN REARRANGEMENT CATALYST TO 4-HYDROXYACETOPHENONE OXIME, A POLYOXYETHYLENE GLYCOL, POLYVINYLPYRROLIDONE, AND PROPYLENE GLYCOL; SOLUBILITY, STABILITY | THE PROCTER & GAMBLE COMPANY (US) | 1996-04-23 | — | — | US | disclosed |
| US-5484606-A | STABILITY | THE PROCTER & GAMBLE COMPANY (US) | 1996-01-16 | — | — | US | disclosed |
| WO-1995019759-A1 | PROCESS FOR SOLUBILIZING DIFFICULTLY SOLUBLE PHARMACEUTICAL ACTIVES | THE PROCTER & GAMBLE COMPANY (US) | 1995-07-27 | — | — | WO | disclosed |
| WO-1995019792-A1 | PROCESS FOR REDUCING THE PRECIPITATION OF DIFFICULTLY SOLUBLE PHARMACEUTICAL ACTIVES | THE PROCTER & GAMBLE COMPANY (US) | 1995-07-27 | — | — | WO | disclosed |
| EP-0591346-A1 | PROCESS FOR SOLUBILIZING DIFFICULTLY SOLUBLE PHARMACEUTICAL ACTIVES | RICHARDSON-VICKS, INC. (US) | 1994-04-13 | — | — | EP | disclosed |
| WO-1993000072-A1 | PROCESS FOR SOLUBILIZING DIFFICULTLY SOLUBLE PHARMACEUTICAL ACTIVES | RICHARDSON VICKS, INC. (US) | 1993-01-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050282879-A1 | Methods and composition for treatment of migraine and symptoms thereof | HRH3, HRH4, HNMT | HRH1 5/4885SMN1; SMN2 2726/4885LMNA 2109/4885 |
| US-20090018205-A1 | METHODS FOR TREATMENT OF MIGRAINE AND SYMPTOMS THEREOF | HNMT, HRH3, HRH4 | HRH1 5/4885SMN1; SMN2 3026/4885LMNA 2521/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.